- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- May 2024
- 139 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- July 2024
- 231 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- May 2022
- 196 Pages
Global
From €2495EUR$2,625USD£2,096GBP
€4991EUR$5,250USD£4,193GBP
- Report
- August 2023
- 250 Pages
Global
From €2367EUR$2,490USD£1,989GBP
- Report
- October 2022
- 270 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- September 2022
- 232 Pages
Global
From €3327EUR$3,500USD£2,795GBP
- Report
- February 2024
- 250 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- February 2022
- 210 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- September 2021
- 111 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2614EUR$2,750USD£2,196GBP
- Report
- October 2021
- 288 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- January 2024
- 243 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- August 2018
- 21 Pages
Global
From €9507EUR$10,000USD£7,986GBP
- Report
- April 2018
United States
From €7600EUR$7,995USD£6,385GBP

Cimzia is a biologic drug used to treat immune disorders such as Crohn's disease, ulcerative colitis, and rheumatoid arthritis. It is a tumor necrosis factor (TNF) blocker, which works by blocking the action of TNF, a protein that plays a role in inflammation. Cimzia is administered by subcutaneous injection and is available in both prefilled syringes and autoinjectors.
The Cimzia market is highly competitive, with several major players offering similar products. These include AbbVie, Amgen, Janssen, and Pfizer. Other companies in the market include UCB, Merck, and Bristol-Myers Squibb. These companies offer a range of products, including biosimilars, which are similar to Cimzia but are not identical.
The Cimzia market is expected to continue to grow in the coming years, driven by increasing demand for treatments for immune disorders. The market is also expected to benefit from the development of new products and technologies, such as biosimilars. Show Less Read more